Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
25 juil. 2023 08h30 HE
|
Third Harmonic Bio
THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical profile THB001 demonstrated evidence of...
Third Harmonic Bio Announces First Quarter 2023 Financial Results
11 mai 2023 17h00 HE
|
Third Harmonic Bio
SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results
29 mars 2023 08h05 HE
|
Third Harmonic Bio
SAN FRANCISCO, March 29, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria
15 déc. 2022 07h00 HE
|
Third Harmonic Bio
-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID -- Evidence of clinical activity observed; full data set to be...
Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference
21 nov. 2022 16h05 HE
|
Third Harmonic Bio
CAMBRIDGE, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and...
Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update
09 nov. 2022 16h15 HE
|
Third Harmonic Bio
Successfully Completed Upsized Initial Public Offering Providing Funding Through 2025 Patient Dosing Underway in Phase 1b Chronic Inducible Urticaria Clinical Trial CAMBRIDGE, Mass., Nov. 09, 2022 ...
Third Harmonic Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
19 sept. 2022 16h10 HE
|
Third Harmonic Bio
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for...
Third Harmonic Bio Announces Pricing of Upsized Initial Public Offering
14 sept. 2022 19h33 HE
|
Third Harmonic Bio
CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for...
Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directors
09 août 2022 08h30 HE
|
Third Harmonic Bio
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment...
Julie Person Joins Third Harmonic Bio as Chief Administrative Officer
28 juin 2022 14h14 HE
|
Third Harmonic Bio
CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of...